The NR4A nuclear receptors as potential targets for anti-aging interventions.
Identifieur interne : 000398 ( PubMed/Curation ); précédent : 000397; suivant : 000399The NR4A nuclear receptors as potential targets for anti-aging interventions.
Auteurs : Michael R. Paillasse [France] ; Philippe De Medina [France]Source :
- Medical hypotheses [ 1532-2777 ] ; 2015.
English descriptors
- KwdEn :
- Aging (drug effects), Aging (physiology), Caloric Restriction, DNA Repair (physiology), Diabetes Mellitus (drug therapy), Drug Delivery Systems (methods), Fatty Acids (metabolism), Humans, Metabolic Syndrome X (drug therapy), Mitochondrial Turnover (physiology), Models, Biological, Nuclear Receptor Subfamily 4, Group A, Member 1 (metabolism), Parkinson Disease (drug therapy).
- MESH :
- chemical , metabolism : Fatty Acids, Nuclear Receptor Subfamily 4, Group A, Member 1.
- drug effects : Aging.
- drug therapy : Diabetes Mellitus, Metabolic Syndrome X, Parkinson Disease.
- methods : Drug Delivery Systems.
- physiology : Aging, DNA Repair, Mitochondrial Turnover.
- Caloric Restriction, Humans, Models, Biological.
Abstract
The development of innovative anti-aging strategy is urgently needed to promote healthy aging and overcome the occurrence of age-related diseases such as cancer, diabetes, cardiovascular and neurodegenerative diseases. Genomic instability, deregulated nutrient sensing and mitochondrial dysfunction are established hallmark of aging. Interestingly, the orphan nuclear receptors NR4A subfamily (NR4A1, NR4A2 and NR4A3) are nutrient sensors that trigger mitochondria biogenesis and improve intrinsic mitochondrial function. In addition, NR4A receptors are components of DNA repair machinery and promote DNA repair. Members of the NR4A subfamily should also be involved in anti-aging properties of hormesis since these receptors are induced by various form of cellular stress and stimulate protective cells response such as anti-oxidative activity and DNA repair. Previous studies reported that NR4A nuclear receptors subfamily is potential therapeutic targets for the treatment of age related disorders (e.g. metabolic syndromes, diabetes and neurodegenerative diseases). Consequently, we propose that targeting NR4A receptors might constitute a new approach to delay aging and the onset of diseases affecting our aging population.
DOI: 10.1016/j.mehy.2014.12.003
PubMed: 25543265
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000402
Links to Exploration step
pubmed:25543265Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The NR4A nuclear receptors as potential targets for anti-aging interventions.</title><author><name sortKey="Paillasse, Michael R" sort="Paillasse, Michael R" uniqKey="Paillasse M" first="Michael R" last="Paillasse">Michael R. Paillasse</name><affiliation wicri:level="1"><nlm:affiliation>Affichem, Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Affichem, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="De Medina, Philippe" sort="De Medina, Philippe" uniqKey="De Medina P" first="Philippe" last="De Medina">Philippe De Medina</name><affiliation wicri:level="1"><nlm:affiliation>Affichem, Toulouse, France. Electronic address: phildemedina@yahoo.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Affichem, Toulouse</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25543265</idno><idno type="pmid">25543265</idno><idno type="doi">10.1016/j.mehy.2014.12.003</idno><idno type="wicri:Area/PubMed/Corpus">000402</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000402</idno><idno type="wicri:Area/PubMed/Curation">000398</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000398</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The NR4A nuclear receptors as potential targets for anti-aging interventions.</title><author><name sortKey="Paillasse, Michael R" sort="Paillasse, Michael R" uniqKey="Paillasse M" first="Michael R" last="Paillasse">Michael R. Paillasse</name><affiliation wicri:level="1"><nlm:affiliation>Affichem, Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Affichem, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="De Medina, Philippe" sort="De Medina, Philippe" uniqKey="De Medina P" first="Philippe" last="De Medina">Philippe De Medina</name><affiliation wicri:level="1"><nlm:affiliation>Affichem, Toulouse, France. Electronic address: phildemedina@yahoo.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Affichem, Toulouse</wicri:regionArea></affiliation></author></analytic><series><title level="j">Medical hypotheses</title><idno type="eISSN">1532-2777</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aging (drug effects)</term><term>Aging (physiology)</term><term>Caloric Restriction</term><term>DNA Repair (physiology)</term><term>Diabetes Mellitus (drug therapy)</term><term>Drug Delivery Systems (methods)</term><term>Fatty Acids (metabolism)</term><term>Humans</term><term>Metabolic Syndrome X (drug therapy)</term><term>Mitochondrial Turnover (physiology)</term><term>Models, Biological</term><term>Nuclear Receptor Subfamily 4, Group A, Member 1 (metabolism)</term><term>Parkinson Disease (drug therapy)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Fatty Acids</term><term>Nuclear Receptor Subfamily 4, Group A, Member 1</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Aging</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Diabetes Mellitus</term><term>Metabolic Syndrome X</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Delivery Systems</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Aging</term><term>DNA Repair</term><term>Mitochondrial Turnover</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Caloric Restriction</term><term>Humans</term><term>Models, Biological</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The development of innovative anti-aging strategy is urgently needed to promote healthy aging and overcome the occurrence of age-related diseases such as cancer, diabetes, cardiovascular and neurodegenerative diseases. Genomic instability, deregulated nutrient sensing and mitochondrial dysfunction are established hallmark of aging. Interestingly, the orphan nuclear receptors NR4A subfamily (NR4A1, NR4A2 and NR4A3) are nutrient sensors that trigger mitochondria biogenesis and improve intrinsic mitochondrial function. In addition, NR4A receptors are components of DNA repair machinery and promote DNA repair. Members of the NR4A subfamily should also be involved in anti-aging properties of hormesis since these receptors are induced by various form of cellular stress and stimulate protective cells response such as anti-oxidative activity and DNA repair. Previous studies reported that NR4A nuclear receptors subfamily is potential therapeutic targets for the treatment of age related disorders (e.g. metabolic syndromes, diabetes and neurodegenerative diseases). Consequently, we propose that targeting NR4A receptors might constitute a new approach to delay aging and the onset of diseases affecting our aging population.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25543265</PMID><DateCreated><Year>2015</Year><Month>01</Month><Day>21</Day></DateCreated><DateCompleted><Year>2015</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2015</Year><Month>01</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-2777</ISSN><JournalIssue CitedMedium="Internet"><Volume>84</Volume><Issue>2</Issue><PubDate><Year>2015</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Medical hypotheses</Title><ISOAbbreviation>Med. Hypotheses</ISOAbbreviation></Journal><ArticleTitle>The NR4A nuclear receptors as potential targets for anti-aging interventions.</ArticleTitle><Pagination><MedlinePgn>135-40</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.mehy.2014.12.003</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0306-9877(14)00438-1</ELocationID><Abstract><AbstractText>The development of innovative anti-aging strategy is urgently needed to promote healthy aging and overcome the occurrence of age-related diseases such as cancer, diabetes, cardiovascular and neurodegenerative diseases. Genomic instability, deregulated nutrient sensing and mitochondrial dysfunction are established hallmark of aging. Interestingly, the orphan nuclear receptors NR4A subfamily (NR4A1, NR4A2 and NR4A3) are nutrient sensors that trigger mitochondria biogenesis and improve intrinsic mitochondrial function. In addition, NR4A receptors are components of DNA repair machinery and promote DNA repair. Members of the NR4A subfamily should also be involved in anti-aging properties of hormesis since these receptors are induced by various form of cellular stress and stimulate protective cells response such as anti-oxidative activity and DNA repair. Previous studies reported that NR4A nuclear receptors subfamily is potential therapeutic targets for the treatment of age related disorders (e.g. metabolic syndromes, diabetes and neurodegenerative diseases). Consequently, we propose that targeting NR4A receptors might constitute a new approach to delay aging and the onset of diseases affecting our aging population.</AbstractText><CopyrightInformation>Copyright © 2014 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Paillasse</LastName><ForeName>Michael R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Affichem, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Medina</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Affichem, Toulouse, France. Electronic address: phildemedina@yahoo.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>12</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Med Hypotheses</MedlineTA><NlmUniqueID>7505668</NlmUniqueID><ISSNLinking>0306-9877</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005227">Fatty Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C539821">NR4A1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057105">Nuclear Receptor Subfamily 4, Group A, Member 1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D031204" MajorTopicYN="N">Caloric Restriction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004260" MajorTopicYN="N">DNA Repair</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003920" MajorTopicYN="N">Diabetes Mellitus</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005227" MajorTopicYN="N">Fatty Acids</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024821" MajorTopicYN="N">Metabolic Syndrome X</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D063269" MajorTopicYN="N">Mitochondrial Turnover</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="Y">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057105" MajorTopicYN="N">Nuclear Receptor Subfamily 4, Group A, Member 1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>09</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>12</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>12</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>12</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25543265</ArticleId><ArticleId IdType="pii">S0306-9877(14)00438-1</ArticleId><ArticleId IdType="doi">10.1016/j.mehy.2014.12.003</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000398 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000398 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:25543265
|texte= The NR4A nuclear receptors as potential targets for anti-aging interventions.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:25543265" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |